238 related articles for article (PubMed ID: 9767640)
1. Design, synthesis, and biological activities of new thieno[3,2-d] pyrimidines as selective type 4 phosphodiesterase inhibitors.
Crespo MI; Pagès L; Vega A; Segarra V; López M; Doménech T; Miralpeix M; Beleta J; Ryder H; Palacios JM
J Med Chem; 1998 Oct; 41(21):4021-35. PubMed ID: 9767640
[TBL] [Abstract][Full Text] [Related]
2. Functional and biochemical evidence for diazepam as a cyclic nucleotide phosphodiesterase type 4 inhibitor.
Collado MC; Beleta J; Martinez E; Miralpeix M; Domènech T; Palacios JM; Hernández J
Br J Pharmacol; 1998 Mar; 123(6):1047-54. PubMed ID: 9559885
[TBL] [Abstract][Full Text] [Related]
3. Characterization of phosphodiesterase 4 in guinea-pig macrophages: multiple activities, association states and sensitivity to selective inhibitors.
Kelly JJ; Barnes PJ; Giembycz MA
Br J Pharmacol; 1998 May; 124(1):129-40. PubMed ID: 9630352
[TBL] [Abstract][Full Text] [Related]
4. Biarylcarboxylic acids and -amides: inhibition of phosphodiesterase type IV versus [3H]rolipram binding activity and their relationship to emetic behavior in the ferret.
Duplantier AJ; Biggers MS; Chambers RJ; Cheng JB; Cooper K; Damon DB; Eggler JF; Kraus KG; Marfat A; Masamune H; Pillar JS; Shirley JT; Umland JP; Watson JW
J Med Chem; 1996 Jan; 39(1):120-5. PubMed ID: 8568798
[TBL] [Abstract][Full Text] [Related]
5. The ability of phosphodiesterase IV inhibitors to suppress superoxide production in guinea pig eosinophils is correlated with inhibition of phosphodiesterase IV catalytic activity.
Barnette MS; Manning CD; Cieslinski LB; Burman M; Christensen SB; Torphy TJ
J Pharmacol Exp Ther; 1995 May; 273(2):674-9. PubMed ID: 7752069
[TBL] [Abstract][Full Text] [Related]
6. Inhibitors of phosphodiesterase IV (PDE IV) increase acid secretion in rabbit isolated gastric glands: correlation between function and interaction with a high-affinity rolipram binding site.
Barnette MS; Grous M; Cieslinski LB; Burman M; Christensen SB; Torphy TJ
J Pharmacol Exp Ther; 1995 Jun; 273(3):1396-402. PubMed ID: 7791113
[TBL] [Abstract][Full Text] [Related]
7. CDP840: a novel inhibitor of PDE-4.
Perry MJ; O'Connell J; Walker C; Crabbe T; Baldock D; Russell A; Lumb S; Huang Z; Howat D; Allen R; Merriman M; Walls J; Daniel T; Hughes B; Laliberte F; Higgs GA; Owens RJ
Cell Biochem Biophys; 1998; 29(1-2):113-32. PubMed ID: 9631241
[TBL] [Abstract][Full Text] [Related]
8. Identification, characterization, and functional role of phosphodiesterase type IV in cerebral vessels: effects of selective phosphodiesterase inhibitors.
Willette RN; Shiloh AO; Sauermelch CF; Sulpizio A; Michell MP; Cieslinski LB; Torphy TJ; Ohlstein EH
J Cereb Blood Flow Metab; 1997 Feb; 17(2):210-9. PubMed ID: 9040501
[TBL] [Abstract][Full Text] [Related]
9. Suppression of eosinophil function by RP 73401, a potent and selective inhibitor of cyclic AMP-specific phosphodiesterase: comparison with rolipram.
Souness JE; Maslen C; Webber S; Foster M; Raeburn D; Palfreyman MN; Ashton MJ; Karlsson JA
Br J Pharmacol; 1995 May; 115(1):39-46. PubMed ID: 7647982
[TBL] [Abstract][Full Text] [Related]
10. Novel selective PDE IV inhibitors as antiasthmatic agents. Synthesis and biological activities of a series of 1-aryl-2,3-bis(hydroxymethyl)naphthalene lignans.
Iwasaki T; Kondo K; Kuroda T; Moritani Y; Yamagata S; Sugiura M; Kikkawa H; Kaminuma O; Ikezawa K
J Med Chem; 1996 Jul; 39(14):2696-704. PubMed ID: 8709099
[TBL] [Abstract][Full Text] [Related]
11. Syntheses and evaluation of pyrido[2,3-dlpyrimidine-2,4-diones as PDE 4 inhibitors.
Nam G; Yoon CM; Kim E; Rhee CK; Kim JH; Shin JH; Kim SH
Bioorg Med Chem Lett; 2001 Mar; 11(5):611-4. PubMed ID: 11266153
[TBL] [Abstract][Full Text] [Related]
12. Selective inhibitors of cyclic AMP-specific phosphodiesterase: heterocycle-condensed purines.
Sawanishi H; Suzuki H; Yamamoto S; Waki Y; Kasugai S; Ohya K; Suzuki N; Miyamoto K; Takagi K
J Med Chem; 1997 Sep; 40(20):3248-53. PubMed ID: 9379444
[TBL] [Abstract][Full Text] [Related]
13. 1,4-Cyclohexanecarboxylates: potent and selective inhibitors of phosophodiesterase 4 for the treatment of asthma.
Christensen SB; Guider A; Forster CJ; Gleason JG; Bender PE; Karpinski JM; DeWolf WE; Barnette MS; Underwood DC; Griswold DE; Cieslinski LB; Burman M; Bochnowicz S; Osborn RR; Manning CD; Grous M; Hillegas LM; Bartus JO; Ryan MD; Eggleston DS; Haltiwanger RC; Torphy TJ
J Med Chem; 1998 Mar; 41(6):821-35. PubMed ID: 9526558
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and evaluation of polycyclic pyrazolo[3,4-d]pyrimidines as PDE1 and PDE5 cGMP phosphodiesterase inhibitors.
Xia Y; Chackalamannil S; Czarniecki M; Tsai H; Vaccaro H; Cleven R; Cook J; Fawzi A; Watkins R; Zhang H
J Med Chem; 1997 Dec; 40(26):4372-7. PubMed ID: 9435906
[TBL] [Abstract][Full Text] [Related]
15. Fused pyrimidine based inhibitors of phosphodiesterase 7 (PDE7): synthesis and initial structure-activity relationships.
Kempson J; Pitts WJ; Barbosa J; Guo J; Omotoso O; Watson A; Stebbins K; Starling GC; Dodd JH; Barrish JC; Felix R; Fischer K
Bioorg Med Chem Lett; 2005 Apr; 15(7):1829-33. PubMed ID: 15780616
[TBL] [Abstract][Full Text] [Related]
16. Characterization of CHO-K1 cells stably expressing PDE-IV enzymes. Whole-cell cAMP determinations vs broken-cell enzymatic assays.
Pon DJ; Plant M; Tkach J; Boulet L; Muise E; Allen RA; Rodger IW
Cell Biochem Biophys; 1998; 29(1-2):159-78. PubMed ID: 9631244
[TBL] [Abstract][Full Text] [Related]
17. Phosphodiesterase 4 in macrophages: relationship between cAMP accumulation, suppression of cAMP hydrolysis and inhibition of [3H]R-(-)-rolipram binding by selective inhibitors.
Kelly JJ; Barnes PJ; Giembycz MA
Biochem J; 1996 Sep; 318 ( Pt 2)(Pt 2):425-36. PubMed ID: 8809029
[TBL] [Abstract][Full Text] [Related]
18. Dual inhibition of human type 4 phosphodiesterase isostates by (R, R)-(+/-)-methyl 3-acetyl-4-[3-(cyclopentyloxy)-4-methoxyphenyl]-3- methyl-1-pyrrolidinecarboxylate.
Tian G; Rocque WJ; Wiseman JS; Thompson IZ; Holmes WD; Domanico PL; Stafford JA; Feldman PL; Luther MA
Biochemistry; 1998 May; 37(19):6894-904. PubMed ID: 9578576
[TBL] [Abstract][Full Text] [Related]
19. Induction of apoptosis by an inhibitor of cAMP-specific PDE in malignant murine carcinoma cells overexpressing PDE activity in comparison to their nonmalignant counterparts.
Marko D; Romanakis K; Zankl H; Fürstenberger G; Steinbauer B; Eisenbrand G
Cell Biochem Biophys; 1998; 28(2-3):75-101. PubMed ID: 9515161
[TBL] [Abstract][Full Text] [Related]
20. Novel heterocyclic-fused pyridazinones as potent and selective phosphodiesterase IV inhibitors.
Dal Piaz V; Giovannoni MP; Castellana C; Palacios JM; Beleta J; Doménech T; Segarra V
J Med Chem; 1997 May; 40(10):1417-21. PubMed ID: 9154964
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
